Meta-analysis of the prognostic significance of ASXL1 mutation in AML patients with intermediate-risk cytogenetic versus intermediate-risk cytogenetic + NPM1 mutation for Overall survival (OS). This evidence concerns the gene NPM1 and acute myeloid leukemia.